As of May 30, 2022, the company has 14,526,005 issued shares (including 10,087 treasury shares held by SHL, which are dormant shares and have no rights) with a nominal value of NIS 0.01 each (Corresponding to 14,515,918 voting rights)
As of May 30, 2022, SHL was aware of the following shareholders with more than 3% of all voting rights in the company:
Including Treasury Shares
Excluding Treasury Shares %
Cai Mengke and Shen Kun
|More Provident Funds||894,332|
|Value Base Group||837,865|
|Sphera Funds Management Ltd.||596,000|
|Danbar Finance Ltd.||540,000|
The above table of Significant Shareholders reflects both actual holdings as of May 30, 2022, excluding options and any other purchase positions, after deducting from the total number of shares outstanding 10,087 Ordinary Shares held by SHL, and actual holdings as of May 30, 2022 calculated including ordinary shares held by SHL, all as indicated above, but does not reflect holdings on a fully diluted basis. All in accordance with notifications received by the Company from its shareholders as of May 30, 2022.
Disclosure of Management Transactions
SHL Telemedicine has to report to SIX Swiss Exchange all transactions of SHL shares and options made by the Board of Directors and the executive management. The disclosure of management transactions is intended as a means of furthering the supply of information to investors. Such disclosure provides investors with additional qualitative insight with regard to their investment decision.
Click here for the Management Transaction disclosure of SHL Telemedicine on the SIX-Platform.